STOCK TITAN
  1. Home
  2. News
  3. ICPT

Intercept Pharmaceuticals Inc - ICPT STOCK NEWS

Welcome to our dedicated page for Intercept Pharmaceuticals news (Ticker: ICPT), a resource for investors and traders seeking the latest updates and insights on Intercept Pharmaceuticals stock.

Intercept Pharmaceuticals Inc (ICPT) is a biopharmaceutical innovator focused on developing therapies for progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). This page provides investors and medical professionals with centralized access to official press releases, clinical trial updates, and regulatory developments.

Stay informed about ICPT's advancements in hepatology through verified updates on drug approvals, partnership announcements, and financial results. Our curated collection includes:

• Clinical trial progress for novel liver disease treatments
• FDA regulatory updates and milestone achievements
• Financial performance reports including earnings calls
• Strategic collaborations with research institutions

Bookmark this page for real-time access to Intercept Pharmaceuticals' latest developments. Check regularly for updates impacting therapeutic innovation and investment considerations in the hepatology sector.

News

Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Rhea-AI Summary
Intercept Pharmaceuticals to participate in fireside chats and investor meetings at upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.84%
Tags
conferences
-
News

Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates

Rhea-AI Summary
Intercept Pharmaceuticals reports Q2 2023 financial results with net sales of $83.7 million, representing 17% growth YoY. The company updates its full-year 2023 net sales guidance to $320-$340 million. Intercept expects to achieve meaningful profitability in 2024. The OCA-bezafibrate combination program shows positive results in Phase 2 studies for the treatment of PBC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
earnings
-
News

Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

Rhea-AI Summary
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) to announce Q2 2023 financial results on August 2, 2023, with a conference call and webcast. Participants can access the live webcast on the company's investor page and register to ask questions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
earnings
News

Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
News

Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Rhea-AI Summary
Intercept Pharmaceuticals announced new results from a planned interim analysis of its Phase 2 study assessing improvements in serum biomarkers of hepatic function, cholestasis, and inflammation in patients with primary biliary cholangitis (PBC) after treatment with a combination of obeticholic acid (OCA) and bezafibrate. The combination was effective in normalizing multiple biochemical markers associated with PBC-induced liver damage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
News

Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
News

Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.84%
Tags
none
-
News

Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
-
News

Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

Rhea-AI Summary
Intercept Pharmaceuticals received disappointing outcome from the FDA Gastrointestinal Drugs Advisory Committee Meeting regarding the approval of obeticholic acid (OCA) for the treatment of pre-cirrhotic fibrosis due to NASH. Twelve out of 16 voting-eligible members voted against the benefits of OCA, while 15 members voted to defer approval until clinical outcome data from trial 747-303 are submitted and reviewed. Intercept will host a conference call on May 22, 2023, to discuss the meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.72%
Tags
none
News

Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

Rhea-AI Summary
Intercept Pharmaceuticals, Inc. announces trading halt as FDA's Gastrointestinal Drugs Advisory Committee reviews obeticholic acid as a treatment for pre-cirrhotic fibrosis due to NASH. FDA's target action date is June 22, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock ICPT logo
Intercept Pharmaceuticals Inc

Nasdaq:ICPT

ICPT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ICPT Stock Data

794.69M
40.45M
3.13%
81.3%
24.24%
Biotechnology
Healthcare
Link
United States
Morristown